Group 1 - The CRO concept index increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Weiming hitting the daily limit [1][2] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1][2] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks attracting over 50 million yuan [2][3] Group 2 - The leading stock in terms of net inflow was WuXi AppTec, with a net inflow of 1.04 billion yuan, followed by Fosun Pharma, Dezhan Health, and Chengdu Xian Dao with net inflows of 233 million yuan, 126 million yuan, and 93.8 million yuan respectively [2][3] - The highest net inflow ratios were observed in Dezhan Health, ST Weiming, and Baohua Pharmaceutical, with ratios of 26.23%, 17.45%, and 16.34% respectively [3][4] - The trading volume and turnover rates for key stocks in the CRO sector showed significant activity, with WuXi AppTec having a turnover rate of 4.09% and a price increase of 8.02% [3][4]

Group 1 - The CRO concept sector increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Unimed hitting the daily limit [1] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks exceeding 50 million yuan in net inflow, led by WuXi AppTec with 1.04 billion yuan [2][3] Group 2 - The top stocks by net inflow ratio included Dezhan Health, ST Unimed, and Baohua Pharmaceutical, with net inflow ratios of 26.23%, 17.45%, and 16.34% respectively [3] - The top stocks in the CRO concept by net inflow included WuXi AppTec, Fosun Pharma, and Dezhan Health, with net inflows of 1.04 billion yuan, 233.4 million yuan, and 126.1 million yuan respectively [3][4] - Stocks with significant declines included Sichuan Shuangma, ST Biology, and Hitec Biotech, which fell by 3.73%, 3.03%, and 2.67% respectively [1][6]

证券日报网讯德展健康8月29日在互动平台回答投资者提问时表示，截至2025年上半年，海南德澄国际 医康养综合体项目部分建筑物主体结构已封顶，其他建筑主体结构建设稳步推进。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article is that Dezhang Health (000813) is making progress on its Hainan Decheng International Medical and Health Complex project, with some main structures already topped off and others advancing steadily towards completion [1] Group 2 - As of August 29, 2023, the company responded to investor inquiries regarding the status of the project [1] - The project is expected to reach significant construction milestones by the first half of 2025 [1]

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

Group 1 - The core point of the news is that Shanghai Yueye has successfully auctioned and transferred all shares of Dezhan Health, eliminating a long-standing potential selling pressure in the market [1] - The shareholding structure of Dezhan Health has become clearer, with the largest shareholder being Xinjiang Kaidi Investment Co., Ltd. holding 19.54% and the second largest being Merrill Holdings Group Ltd. holding 8.87% [1] - The actual controller of the company is the State-owned Assets Supervision and Administration Commission of the People's Government of Xinjiang Uygur Autonomous Region [1] Group 2 - Dezhan Health is a leading domestic company engaged in the research, production, and sales of cardiovascular drugs [2] - The company is focusing on deepening its technology innovation strategy and expanding its business layout towards "pharmaceuticals + medical + health" [2] - Dezhan Health has established a collaboration with the Chinese Academy of Engineering and is actively promoting various research projects with renowned institutions [2] Group 3 - The company has made progress in its product pipeline, with IND application for WYY injection for stroke indications expected to be submitted in the second half of the year [2] - The company plans to submit a registration application for CBD raw materials to the FDA in the second half of the year, with production expected to commence in the second half of 2025 [2] - The company is also involved in clinical trials for various cancer-related products, including VGX-3100 for cervical precancerous lesions and new drug exploration for COPD and pancreatic cancer [2]

Group 1 - The company held its 34th meeting of the 8th Board of Directors on August 26, 2025, with all 9 directors present, confirming compliance with legal and procedural requirements [1][2] - The board approved a proposal to amend the company's articles of association following the completion of a share repurchase plan, which involved the repurchase of 67,850,450 shares [1][2] - The board elected several candidates for the 9th Board of Directors, including Wei Zheming, Liu Wei, Gao Tao, Liu Xiaofeng, Fu Peng, and Zhan Haitan, with unanimous support from all directors [2][3] Group 2 - The board's proposal to hold the second extraordinary general meeting of shareholders on September 12, 2025, was approved, with a registration date set for September 5, 2025 [4] - The meeting will be conducted in a hybrid format, combining on-site and online voting, at a specified location in Urumqi, Xinjiang [4] - Relevant documents, including the resolutions from the board meeting and the nomination committee's records, will be made available for review [4][5]

Meeting Information - The company, 德展大健康股份有限公司, will hold its second extraordinary general meeting of shareholders on September 12, 2025, at 14:30 [1] - Shareholders registered by the close of trading on September 5, 2025, are entitled to attend the meeting and vote [2] - The meeting will be held at the company's conference room on the 15th floor [2] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system on September 12, 2025, during specified time slots [1][11] - Specific voting procedures for both non-cumulative and cumulative voting proposals are outlined, including the need for shareholders to allocate their voting rights appropriately [9][11] Agenda Items - The meeting will include proposals for the election of non-independent and independent directors for the company's ninth board of directors [4][5] - The election of six non-independent directors and three independent directors is on the agenda [4][5] Proxy Voting - Shareholders can appoint a proxy to attend and vote on their behalf, with a template for the proxy authorization provided [2][14] - The proxy does not need to be a shareholder of the company [2]

上市公司独立董事候选人声明与承诺 声明人肖良林作为德展大健康股份有限公司第九届董事会 独立董事候选人，已充分了解并同意由提名人德展大健康股份有 限公司董事会提名为德展大健康股份有限公司（以下简称该公司） 第九届董事会独立董事候选人。现公开声明和保证，本人与该公 司之间不存在任何影响本人独立性的关系，且符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独 立董事候选人任职资格及独立性的要求，具体声明并承诺如下事 项： 一、本人已经通过德展大健康股份有限公司第八届董事会 提名委员会或者独立董事专门会议资格审查，提名人与本人不 存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是□否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八 条等规定不得担任公司董事的情形。 ☑ 是□否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》 和深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是□否 —1— 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 ☑ 是□否 如否，请详细说明： 五、本人已经参加培训并取得证券交易所认可的 ...

上市公司独立董事候选人声明与承诺 声明人耿利航作为德展大健康股份有限公司第九届董事会 独立董事候选人，已充分了解并同意由提名人德展大健康股份有 限公司董事会提名为德展大健康股份有限公司（以下简称该公司） 第九届董事会独立董事候选人。现公开声明和保证，本人与该公 司之间不存在任何影响本人独立性的关系，且符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独 立董事候选人任职资格及独立性的要求，具体声明并承诺如下事 项： 一、本人已经通过德展大健康股份有限公司第八届董事会 提名委员会或者独立董事专门会议资格审查，提名人与本人不 存在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是□否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八 条等规定不得担任公司董事的情形。 ☑ 是□否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》 和深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是□否 —1— 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 六、本人担任独立董事不会违反《中华人民共和国公务员 法》的相关规定。 ☑ ...